Respiratory disease in systemic lupus erythematosus: correlation with results of laboratory tests and histological appearance of muscle biopsy specimens

S A Evans, N D Hopkinson, W J M Kinnear, L Watson, R J Powell, I D A Johnston

Abstract

Background In systemic lupus erythematosus, certain laboratory tests and evidence from muscle biopsy specimens of lymphocytic vasculitis reflect disease activity. A study was designed to determine if such indices predict respiratory lesions, and in particular whether the presence of vasculitis in quadriceps muscle reflects respiratory muscle function.

Methods Twenty seven 27 patients with systemic lupus erythematosus were studied, ten of whom were consecutive untreated patients and 17 having clinically active disease and being treated. They were prospectively evaluated on the basis of erythrocyte sedimentation rate, lymphocyte count, C3 degradation products, quadriceps muscle biopsy, spirometry, lung volumes, carbon monoxide transfer factor, and mouth pressure during a maximal sniff.

Results Lung function test results were abnormal in 12 patients. Vital capacity was reduced in seven, carbon monoxide transfer factor capacity in five, and mouth pressure was low (<70% predicted) in ten. Lymphocytic vasculitis was seen in the muscle biopsy specimens of ten patients. No correlation was found between laboratory tests and lung function or mouth pressure, or between the presence of lymphocytic vasculitis and mouth pressure. In untreated patients, those with lymphocytic vasculitis had lower spirometric values.

Conclusions In systemic lupus erythematosus, evidence from muscle biopsy specimens of lymphocytic vasculitis is not predictive of impaired inspiratory muscle function as measured by mouth pressure. In untreated patients there were relationships between some laboratory test results and respiratory function, but this was not the case for the whole group. In systemic lupus erythematosus, laboratory tests and evidence from muscle biopsy specimens of lymphocytic vasculitis are therefore unlikely to be helpful in the assessment of respiratory disease.

In systemic lupus erythematosus, respiratory symptoms occur in 44–65% of patients and pulmonary function tests give abnormal results in 67–88%. The commonest abnormalities are reduced carbon monoxide transfer factor and lung volumes, but reductions in static mouth pressures have been reported, which raise the possibility of respiratory muscle weakness as a feature of this disease.

Lymphocyte count, anti-DNA antibody titres, immune complexes and complement abnormalities are reported to reflect disease activity in active lupus nephritis, but changes in such tests do not parallel episodes of acute cerebral lupus erythematosus. The extent to which pulmonary involvement can be predicted by laboratory tests is unclear. Grennan and coworkers found that C3, C4, and DNA binding capacity did not correlate with pulmonary involvement in 22 patients with systemic lupus erythematosus, the majority of whom were on treatment. The value of other laboratory tests in predicting lung involvement, especially in untreated patients, remains unknown.

Histological evidence of lymphocytic vasculitis in muscle biopsy specimens is a notable finding in connective tissue disorders, and demonstrates muscle vascular involvement that is often subclinical but implies systemic disease activity. Lymphocytic vasculitis can occur with a normal serum complement and lymphocyte count, and may be an independent predictor of disease activity. The degree to which histological evidence of lymphocytic vasculitis in limb muscles reflects respiratory muscle strength has not been investigated.

We have therefore prospectively studied a group of treated and untreated patients with systemic lupus erythematosus to determine if laboratory tests can predict lung disease, and whether lymphocytic vasculitis in quadriceps muscle is paralleled by a reduction in inspiratory muscle strength.

Patients and methods

Patients

The study population was recruited prospectively from the connective tissue disease/immunology outpatient clinic and consisted of two groups: group 1—consecutive newly presenting untreated patients; and group 2—treated patients with active disease from
whom a muscle biopsy specimen was taken as part of their disease assessment. There was no selection on the basis of respiratory symptoms.

All patients with systemic lupus erythematosus satisfied at least four of the revised American Rheumatism Association criteria. Twenty seven patients were studied (26 of whom were female) with a median age of 44 years (range 20–83); eight were current smokers and five were past smokers. Ten patients had received no treatment, but 14 had been treated with prednisolone, 11 with hydroxychloroquine, and nine with azathioprine. Of the total, 16 patients were referred by their general practitioner and six by internal hospital referral, and five were tertiary referrals.

**METHODS**

Respiratory symptoms were recorded for all new untreated patients. Investigations for each patient were completed within one week and included lymphocyte count (Coulter counter), erythrocyte sedimentation rate (Westergren), search for antibodies to ribonucleoprotein (RNP), Smith (Sm), Ro and La, and quantitation of plasma C3 degradation products (C3dg) by double decker rocket immunoelectrophoresis adapted from the method of Brandslund et al.24

Biopsy specimens from the vastus lateralis muscle were obtained by a lateral approach in

....

**Table 1**

<table>
<thead>
<tr>
<th>FEV₁, FVC</th>
<th>TLC</th>
<th>Kco</th>
<th>TLC</th>
<th>Pmo</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (n = 10)</td>
<td>85 (28)</td>
<td>81 (26)</td>
<td>91 (23)</td>
<td>101 (14)</td>
</tr>
<tr>
<td>Elevated (n = 17)</td>
<td>99 (18)</td>
<td>92 (12)</td>
<td>81 (20)</td>
<td>89 (23)</td>
</tr>
<tr>
<td>C3dg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (n = 19)</td>
<td>97 (21)</td>
<td>92 (18)</td>
<td>89 (17)</td>
<td>93 (13)</td>
</tr>
<tr>
<td>Elevated (n = 8)</td>
<td>88 (26)</td>
<td>80 (18)</td>
<td>74 (28)</td>
<td>93 (32)</td>
</tr>
<tr>
<td>LV</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent (n = 12)</td>
<td>95 (24)</td>
<td>87 (20)</td>
<td>93 (21)</td>
<td>93 (15)</td>
</tr>
<tr>
<td>Present (n = 10)</td>
<td>87 (22)</td>
<td>85 (21)</td>
<td>81 (16)</td>
<td>95 (17)</td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (n = 7)</td>
<td>89 (26)</td>
<td>87 (26)</td>
<td>97 (23)</td>
<td>99 (12)</td>
</tr>
<tr>
<td>Low* (n = 20)</td>
<td>96 (21)</td>
<td>88 (16)</td>
<td>81 (19)</td>
<td>92 (23)</td>
</tr>
</tbody>
</table>

Lung function is given as mean (SD) % predicted.

ESR—erythrocyte sedimentation rate (elevated is $>20$ mm in one hour); C3dg—C3 degradation products (elevated is $>15$ units/ml); LV—lymphocytic vasculitis; FEV₁—forced expiratory volume in one second; FVC—forced vital capacity; TLC—carbon monoxide transfer factor; Kco—transfer coefficient; TLC—total lung capacity; Pmo—mouth pressure.

*Low lymphocyte count is $<1.5\times10^{10}$/ml.
In the untreated patients, relationships between lung function and laboratory results were as follows. The percentage predicted TLC correlated with lymphocyte count (p < 0.01, r = 0.78, fig 2), and those with lymphocytic vasculitis shown on muscle biopsy specimens had lower percentage predicted FEV1 and FVC than those without (p < 0.002, p < 0.05 respectively). However, lung function did not correlate with laboratory results in the treated patients or in the combined group. Furthermore, histological evidence of lymphocytic vasculitis was not predictive of lower Pmo values (p = 0.95). Type II fibre atrophy was not predictive of any respiratory indices. Antibodies to Ro or Ro with La were not associated with abnormal lung function results or the presence of lymphocytic vasculitis.

Discussion
In systemic lupus erythematosus a number of laboratory tests may be used clinically to assess the presence and activity of nephritis.13-17 We have tried to establish if it is similarly possible to predict the presence of respiratory disease. Our study shows that, in general, current laboratory tests and histological evidence of lymphocytic vasculitis in muscle biopsy specimens do not reflect abnormalities of lung function.

In this study abnormal lung function results were found in 44% of patients. This contrasts with previous studies, which have shown a higher prevalence of abnormalities of lung function of 67-88%.1 4 6-8 19 Likewise, the prevalence of respiratory symptoms (40% of newly presenting untreated patients) was also lower than in previous studies (44-65%).1 5 19 There are several possible reasons for our lower rate of abnormalities. In some previous studies the selection criteria are not stated, and hence bias towards those with severe disease or respiratory symptoms cannot be excluded.1 19 A similar bias may also occur in studies undertaken at tertiary referral centres for systemic lupus erythematosus.1 4 18 In contrast to previous studies, we recruited a group of newly presenting untreated patients, so we are likely to have included a larger proportion of untreated patients (37%). We consequently may have seen patients at an earlier stage of their disease. Finally, studies vary in their definition of an abnormal lung function value, some taking <80% predicted as abnormal for TLC. If we adopt this criterion, our overall prevalence of abnormalities rises to 52%, although this is still comparatively low. The true prevalence of abnormalities of lung function in systemic lupus erythematosus remains unclear, but in view of the unselected nature of our patients (including both treated and untreated), our estimate may be more representative.

Several investigators have found that laboratory results correlate with the presence, severity, and treatment response of active lupus nephritis.13-17 However, there have been few attempts to relate lung disease to results of laboratory tests. Genninan et al18 studied 22 patients, 17 of whom were currently on corticosteroids, and found no correlation between reduced TLCO and C3, C4, DNA binding capacity, or rheumatoid factor positivity. However, Gibson et al19 found an unspecified "weak correlation" between lung function abnormalities and higher levels of antinuclear factor and DNA binding in 30 patients, 26 of whom were receiving corticosteroids at the time of assessment. Our study contrasts with these studies in several ways. First, in addition to conventional laboratory markers of disease activity we quantified serum C3dg, which is a more sensitive indicator of complement activation than total C3 and C4 levels, which are dependent on the balance between synthesis and activation.27 Furthermore, we felt that the presence of lymphocytic vasculitis in muscle is likely to be indicative of systemic disease activity.20 Second, we have also studied a group of untreated patients and are therefore able to exclude treatment effects. It is possible that treatment could alter laboratory indices without a corresponding effect on lung function, or could itself adversely affect lung function (as in the case of steroid induced myopathy).

Our finding that laboratory tests and lung function are not correlated in patients with systemic lupus erythematosus is in broad agreement with previous work, and contrasts with renal disease in this condition. The fact that the few associations present were in the untreated group (that is, between lymphocytic vasculitis and FEV1 and FVC) may suggest that treatment effects may obscure associations between laboratory indices and lung function. However, other reasons for the lack of correlation could be that active disease was confined to other organs, or that inappropriate measures of lung function were used. Alternatively, there may be some patients who had previous lung involvement, with permanent changes in lung function, in whom the disease is now quiescent and results of laboratory tests normal, and others for whom abnormal laboratory may presage future lung involvement.

Antibodies to Ro, or Ro with La were not associated with abnormal lung function results or with the presence of lymphocytic vasculitis,
in contrast to their association with the development of renal disease in systemic lupus erythematosus, and chest symptoms in primary Sjögren's syndrome.

The relationship between respiratory muscle strength and immunological indices has not been examined previously. Pmo during a maximal sniff was chosen as a measurement of global inspiratory muscle strength as it correlates well with esophageal sniff pressures (Poes), and does not require the passage of an esophageal balloon/transducer. Static mouth pressures (Pimax) were not used as they are less reproducible and have a wider normal range than sniff pressures. Sniff Poes has also been shown to be useful in discriminating between those who have a low Pimax caused by poor technique and those who have inspiratory weakness. There are conflicting views about respiratory muscle function in systemic lupus erythematosus, especially in the aetiology of shrinking lung syndrome, but our results show that low Pmo during a maximal sniff is common (37%) and that it can be markedly reduced, with four of the patients having a Pmo below 50% predicted. We have chosen <70% predicted as "low," but acknowledge that this is rather arbitrary. Previous authors have suggested use of the mean minus two standard deviations to derive a lower limit of the normal range for sniff pressures. This, however, is problematical, as the distribution of Pmo during a maximal sniff in our reference population was skewed to the right. We hypothesised that lymphocytic vasculitis in biopsy specimens of quadriceps muscle might be associated with a reduction in Pmo but we were unable to find such a relationship. This could be because lymphocytic vasculitis is not associated with weakness of the involved muscle (and we have not investigated this for the quadriceps), or because muscle disease in systemic lupus erythematosus is patchy in distribution.

In summary, although we have found some associations between laboratory results and lung function in untreated patients, we conclude that these tests are unlikely to be clinically helpful in the assessment of respiratory disease in systemic lupus erythematosus. Whether such tests can predict the progression of respiratory disease in systemic lupus erythematosus remains unanswered and would require a longitudinal study. Because abnormalities are common and often asymptomatic, routine testing of respiratory function in this condition would seem indicated.

We wish to acknowledge and thank Dr D K Robson, Consultant Neuropathologist, and Dr J S Lowe, Reader and Honorary Consultant in Neuropathology, for their help and expertise in interpreting the muscle biopsy material and for the photomicrograph of lymphocytic vasculitis.

Respiratory disease in systemic lupus erythematosus: correlation with results of laboratory tests and histological appearance of muscle biopsy specimens.
S A Evans, N D Hopkinson, W J Kinnear, L Watson, R J Powell and I D Johnston

Thorax 1992 47: 957-960
doi: 10.1136/thx.47.11.957

Updated information and services can be found at:
http://thorax.bmj.com/content/47/11/957

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/